EQUITY RESEARCH MEMO
MediVax
Generated 5/24/2026
Executive Summary
Conviction (model self-assessment)65/100
MediVax is a French preclinical biotechnology company focused on developing novel vaccine platforms for infectious diseases and oncology. Founded in 2018 and headquartered in Paris, the company leverages proprietary technologies to enhance immunogenicity and enable rapid response to emerging pathogens. Its pipeline includes vaccine candidates for viral infections and therapeutic cancer vaccines. With $115 million raised to date, MediVax is positioned to advance its platform toward clinical development, targeting both prophylactic and therapeutic applications.
Upcoming Catalysts (preview)
- Q3 2026IND/CTA filing for lead vaccine candidate70% success
- Q4 2026Strategic partnership or licensing deal for platform60% success
- Q3 2026Publication of preclinical efficacy data in peer-reviewed journal80% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)